Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia

Few treatment options are available for acute myeloid leukemia (AML) patients. DCLL9718A is an antibody-drug conjugate that targets C-type lectin-like molecule-1 (CLL-1). This receptor is prevalent on monocytes, neutrophils, and AML blast cells, and unlike CD33, is not expressed on hematopoietic ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Leipold, Douglas D., Figueroa, Isabel, Masih, Shabkhaiz, Latifi, Brandon, Yip, Victor, Shen, Ben-Quan, Dere, Randall C., Carrasco-Triguero, Montserrat, Lee, M. Violet, Saad, Ola M., Liu, Luna, He, Jintang, Su, Dian, Xu, Keyang, Vuillemenot, Brian R., Laing, Steven T., Schutten, Melissa, Kozak, Katherine R., Zheng, Bing, Polson, Andrew G., Kamath, Amrita V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284592/
https://www.ncbi.nlm.nih.gov/pubmed/30183491
http://dx.doi.org/10.1080/19420862.2018.1517565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284592/
https://www.ncbi.nlm.nih.gov/pubmed/30183491
http://dx.doi.org/10.1080/19420862.2018.1517565

Ejemplares similares